We assessed human papillomavirus (HPV) prevalence among HPV-16/18-vaccinated and unvaccinated Finnish male adolescents participating in chlamydia screening 4 years after vaccination with AS04-adjuvanted HPV-16/18 vaccine in 2007 or unvaccinated (n = 149) male adolescents were enrolled in 12 municipalities. First-void urine samples were tested for HPV types 6, 11, 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 59, 66, and 68, and prevalence rates for HPV-16/18, and HPV-11/16/18/31/33/45 were reduced profoundly (0% vs 2.1% [P = .02] and 0.8% vs 5.3 [P = .002], respectively). Overall HPV DNA prevalence was also significantly reduced among HPV-16/18-vaccinated (4.1%) compared with unvaccinated subjects (10.1%) (P = .01). In this post hoc study, a highly significant reduction in HPV prevalence 4 years after vaccination suggests that the bivalent HPV-16/18 vaccine has protective efficacy in men.
Human papillomavirus (HPV) is a major cause of anogenital cancers both in women and men. High-risk HPV type infections are common in men, with worldwide prevalence rates ranging from 5% to 35% or more [1, 2] . More than 20% of men are positive for multiple HPV types [1, 2] . An increase in the number of HPV infections and HPV-related cancers in men has been noted [3] .
There are now 3 licensed HPV vaccines (bivalent HPV-16/18 Cervarix, quadrivalent HPV-6/11/16/18 Gardasil, and nonavalent HPV-6/11/16/18/31/33/45/52/58 Gardasil9), all of which are immunogenic and safe in male recipients [4] . The bivalent vaccine has been reported to be no less immunogenic in boys and men aged 10-18 years than in similarly aged female subjects [5] . The bivalent, quadrivalent, and nonavalent vaccines have yielded excellent efficacy results in female subjects aged 16-26 years [5] . The efficacy of the quadrivalent vaccine against persistent vaccine-type HPV infections has been shown to be >90% in baseline HPV-negative male subjects [6] . We assessed HPV prevalence, including prevalence of the HPV types against which the bivalent vaccine has been shown to be effective in female subjects (HPV types 11, 16, 18, 31, 33, and 45) [7, 8] , in vaccinated and unvaccinated young men approximately 4 years after vaccination.
METHODS

Participants
The study participants were from 12 Finnish municipalities (Hyvinkää, Järvenpää, Joensuu, Jyväskylä, Kemi, Kotka, Kokkola, Kouvola, Lahti, Porvoo, Seinäjoki, and Vantaa). All 395 HPV-vaccinated subjects and 99 hepatitis B virus-vaccinated controls participated in a Chlamydia trachomatis screening trial in asymptomatic 18-year-olds in 2010-2014, in association with a community randomized trial assessing effectiveness of different HPV vaccination strategies in the first 11 municipalities [9] . Fifty asymptomatic, unvaccinated male controls, 18 years of age, were also enrolled in a pilot of ongoing chlamydia screening in the city of Vantaa. After receiving an invitation/information letter, the trial participants provided first-void urine (FVU) samples . Participant anonymity was protected by pseudonymization and stratification, but overall, 11 men tested positive for C. trachomatis and received singledose azithromycin treatment.
Ethical clearances for the separate HPV vaccination and chlamydia screening trials were obtained in 2007 from the ethical review boards of the Pirkanmaa Hospital District, Tampere, Finland (NCT00534638) and the North Ostrobothnia Hospital District, Oulu Finland (No. 310/2009), respectively.
Laboratory Analyses
The FVU samples were analyzed for chlamydia with the Abbott Real Time CT/NG test (Abbott Laboratories), using extracted DNA. The extracted, pseudonymized DNA samples were identified as being from an HPV-16/18-vaccinated, a hepatitis B virus-vaccinated, or an unvaccinated participant and were stored at -20°C.
The extracted DNA from the FVU samples was analyzed using a polymerase chain reaction-based method with modified general primers, followed by a mass extension reaction with type-specific primers that each have a unique molecular weight for a specific type [10] . The HPV DNA genotyping was performed using matrix-assisted laser absorption time-of-flight mass spectrometry on the SEQUENOM platform, a cost-effective, high-throughput HPV genotyping method that performs genotyping of low-risk HPV types 6 and 11; high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; and HPV-66 (not considered a high-risk type). It allowed simultaneous separation and detection of short DNA sequences elongated with a single nucleotide [10] . This semiautomated method has been found proficient using the 2010 WHO HPV Labnet proficiency panel.
Sample Size and Statistical Analysis
We used the Colindale sample size calculation system (version 1.0; Public Health England) for use with Glim4, as described elsewhere [11] . This was used to guarantee that the available samples of study participants provided ≥80% study power at P = .05, for various prevalence rates of HPV-16/18 vaccine and vaccine-covered types HPV-11/16/18/31/33/45 (assuming a range of 10%-30% in swab samples) in unvaccinated 18-yearold men, assuming 95% and 85% vaccine efficacy, respectively [7, 8] . Overall HPV, low-risk, high-risk, cross-protected, and HPV-16/18 vaccine type HPV DNA prevalence rates were compared for statistical significance, using the Fisher exact test.
RESULTS
None of the 395 vaccinated and 3 (2.1%) of the 149 unvaccinated male subjects tested positive for HPV-16/18 (difference, P = .02). In the unvaccinated group, 8 (5.3%) tested positive for HPV types 11, 16, 18, 31, 33, and 45, compared with 3 (0.8%) in the vaccinated group (P = .002) ( Table 1) .
Only a few low-risk HPV types were detectable; there were 4 HPV-6-positive and 1 HPV-11-positive unvaccinated subjects and 3 HPV-6-positive HPV-16/18-vaccinated subjects (difference, P = .04) ( Table 1) . High-risk HPV types were detectable in 9 (2.3%) and 9 (6.0%) of the vaccinated and unvaccinated subjects, respectively (P = .055). Overall, 15 (10.1%) of the 149 unvaccinated and 16 (4.1%) of the 395 HPV-16/18-vaccinated subjects tested positive for any HPV type (P = .01; Table 1 ).
DISCUSSION
We found a highly significant difference in HPV-16/18 prevalence rates between HPV-1-6/18-vaccinated and unvaccinated men. These findings are in line with the reduction in HPV-16/18 prevalence in women after the introduction of a high-coverage national vaccination program using the bivalent vaccine in Scotland [12] , and they suggest a protective efficacy for the HPV-16/18 vaccine in men. Unfortunately, however, small numbers did not allow evaluation of exact vaccine efficacy. NB omission of the word "associated".
The overall HPV prevalence in the samples was low. This may have been partly due to the young age (18-19 years) of the adolescent individuals sampled [1, 2, 9] and partly due to up to 50% lower sensitivity of FVU sampling for the detection of HPV DNA [13] in male subjects, compared with direct anogenital sampling [14] . Possible differences in sexual behavior between the trial participants and with the general adolescent population may also have contributed to the low HPV prevalence [15] . Moreover, participation in the chlamydia screening pilot was not randomized. Thus, even if the background chlamydia rates (a surrogate for risk-taking behavior) were probably comparable in the different subcohorts, biases due to possible behavioral differences between HPV-vaccinated and unvaccinated subjects, who participated in either the screening trial or the screening pilot, were not controlled by randomization.
The results of this observational, post hoc study suggest that the bivalent HPV vaccine has protective efficacy in men against HPV overall, and the HPV types HPV-16/18 and cross-protected and/or low risk types HPV-6/11/31/33/45. Vaccine efficacy for this vaccine has yet to be established in male subjects. Our findings should motivate randomized efficacy studies of the bivalent HPV-16/18 vaccine in a larger sample of male subjects from populations with a higher HPV incidence. 
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